CD19 and B-cell chronic lymphocytic leukemia: The maximum cytolytic response of the three CD20-positive B-CLL patient samples (patients 3, 4 and 5) to both CD19-targeting antibody-derivatives was more pronounced than the response to the standard-of-care reagent MabThera® (Fig. 6A).